#targeted therapy

What Is Targeted Therapy?

Substituting generic, biosimilar or lower-cost medications can reduce costs without sacrificing quality of care.

Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.

The Phase III FRESCO-2 trial showed an improvement in progression-free survival.

Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.

A micro-organosphere model of an individual patient’s cancer may help advance precision oncology.

People with left-sided tumors treated with Vectibix plus standard chemotherapy had an 18% lower risk of death.

Genomic tumor profiling in pediatric patients can clarify diagnosis and treatment, a recent study found.

A passion for improving cardiovascular health for people with cancer

About 1 in 1,000 pregnant women is diagnosed with cancer. Do newer treatments, such as immunotherapy, work in this group of patients?

An Army veteran, retired firefighter and farmer, Jeff Meckstroth, 65, lives in Ohio. He has Stage IV metastatic non-small-cell lung cancer.

Women were at greater risk than men for symptomatic adverse events and hematologic events.

Combination therapy using Taflinar and Mekinst led to improved response for pediatric patients with low-grade gliomas

Experimental KRAS inhibitor adagrasib also shows activity against lung cancer that has spread to the brain.

Compared with men, women had a 34% greater likelihood of adverse events, especially if they received immunotherapy.

Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.

Pediatric patients were matched to therapies targeting specific mutations found in their cancers.